Published in Clin Sci on October 01, 1968
Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: potential mechanism for uremic vascular calcification. Kidney Int (2008) 3.54
Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure. Kidney Int (2009) 2.60
Treatment with pyrophosphate inhibits uremic vascular calcification. Kidney Int (2010) 2.16
Vascular calcification is dependent on plasma levels of pyrophosphate. Kidney Int (2014) 1.57
Inorganic pyrophosphate in plasma in normal persons and in patients with hypophosphatasia, osteogenesis imperfecta, and other disorders of bone. J Clin Invest (1971) 1.55
Outcome predictability of serum alkaline phosphatase in men with pre-dialysis CKD. Nephrol Dial Transplant (2010) 1.19
Recent progress in the treatment of vascular calcification. Kidney Int (2010) 1.18
Identification and characterization of novel tissue-nonspecific alkaline phosphatase inhibitors with diverse modes of action. J Biomol Screen (2009) 1.12
Extracellular pyrophosphate metabolism and calcification in vascular smooth muscle. Am J Physiol Heart Circ Physiol (2011) 1.05
The role of bisphosphonates in diseases of childhood. Eur J Pediatr (2003) 0.89
Impact of age on survival predictability of bone turnover markers in hemodialysis patients. Nephrol Dial Transplant (2013) 0.89
Effects of 1-hydroxyethane-1,1-diphosphonate and dichloromethanediphosphonate on rabbit articular chondrocytes in culture. Biochem J (1979) 0.82
Using a filtration technique to isolate platelet free plasma for assaying pyrophosphate. Clin Lab (2012) 0.80
Alkalosis and Dialytic Clearance of Phosphate Increases Phosphatase Activity: A Hidden Consequence of Hemodialysis. PLoS One (2016) 0.79
Polyphosphates inhibit extracellular matrix mineralization in MC3T3-E1 osteoblast cultures. Bone (2013) 0.77
Genetics of the bone response to bisphosphonate treatments. Clin Cases Miner Bone Metab (2009) 0.76
Towards the revival of alkaline phosphatase for the management of bone disease, mortality and hip fractures. Nephrol Dial Transplant (2014) 0.76
Pre-treatment considerations in childhood hypertension due to chronic kidney disease. World J Nephrol (2015) 0.75
The uptake and metabolism of (32-P)pyrophosphate by mouse calvaria in vitro. Biochem J (1974) 0.75
Impact of magnesium:calcium ratio on calcification of the aortic wall. PLoS One (2017) 0.75
Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med (2001) 9.99
Diabetic clinics today and tomorrow: mini-clinics in general practice. Br Med J (1973) 7.41
Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem (2001) 7.03
Production of collagenase and prostaglandins by isolated adherent rheumatoid synovial cells. Proc Natl Acad Sci U S A (1976) 5.40
TBX1 is responsible for cardiovascular defects in velo-cardio-facial/DiGeorge syndrome. Cell (2001) 4.60
Role of colony stimulating factor-1 in the establishment and regulation of tissue macrophages during postnatal development of the mouse. Development (1994) 3.86
An interleukin 1 like factor stimulates bone resorption in vitro. Nature (1984) 3.71
Isogenic P-fimbrial deletion mutants of pyelonephritogenic Escherichia coli: the role of alpha Gal(1-4) beta Gal binding in virulence of a wild-type strain. Mol Microbiol (1993) 2.80
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol (1998) 2.73
Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A (1999) 2.66
A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med (1998) 2.42
Enterotoxigenicity of Vibrio parahaemolyticus with and without genes encoding thermostable direct hemolysin. Infect Immun (1992) 2.35
Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science (1969) 2.30
Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science (1969) 2.20
Relative contributions of distinct MHC class I-dependent cell populations in protection to tuberculosis infection in mice. Proc Natl Acad Sci U S A (2000) 2.20
Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol (1997) 2.14
Characterization and cloning of the E11 antigen, a marker expressed by rat osteoblasts and osteocytes. Bone (1996) 2.11
Macrophage colony stimulating factor restores in vivo bone resorption in the op/op osteopetrotic mouse. Endocrinology (1990) 2.02
Stimulation by human interleukin 1 of cartilage breakdown and production of collagenase and proteoglycanase by human chondrocytes but not by human osteoblasts in vitro. Biochim Biophys Acta (1984) 2.00
Impairment of macrophage colony-stimulating factor production and lack of resident bone marrow macrophages in the osteopetrotic op/op mouse. J Bone Miner Res (1990) 1.97
Construction of an MR/P fimbrial mutant of Proteus mirabilis: role in virulence in a mouse model of ascending urinary tract infection. Infect Immun (1994) 1.91
Use of dermestid beetles for cleaning bones. Calcif Tissue Int (1980) 1.88
Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl 2 MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcif Tissue Res (1973) 1.85
Contribution of Proteus mirabilis urease to persistence, urolithiasis, and acute pyelonephritis in a mouse model of ascending urinary tract infection. Infect Immun (1993) 1.82
Effects of 1,25-dihydroxycholecalciferol on calcium absorption, muscle weakness, and bone disease in chronic renal failure. Lancet (1974) 1.80
Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest (1989) 1.79
Inorganic pyrophosphate in plasma, urine, and synovial fluid of patients with pyrophosphate arthropathy (chondrocalcinosis or pseudogout). Lancet (1970) 1.77
The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Calcif Tissue Res (1973) 1.77
Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res (1997) 1.72
Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease. Lancet (1980) 1.68
Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature (1966) 1.68
Seroprevalence of Helicobacter pylori in Seventh-Day Adventists and other groups in Maryland. Lack of association with diet. Arch Intern Med (1990) 1.68
Pyrophosphate and diphosphonates in calcium metabolism and their possible role in renal failure. Arch Intern Med (1969) 1.64
Rate of reversal of hypercalcaemia and hypercalciuria induced by vitamin D and its 1alpha-hydroxylated derivatives. Br Med J (1977) 1.62
Seroprevalence of Helicobacter pylori in Chile: vegetables may serve as one route of transmission. J Infect Dis (1993) 1.59
Role of T-lymphocytes in the pathogenesis of herpetic stromal keratitis. Invest Ophthalmol Vis Sci (1984) 1.58
Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest (1993) 1.58
Interleukin-6 does not stimulate bone resorption in neonatal mouse calvariae. J Bone Miner Res (1991) 1.57
Biochemistry and immunology of infectious bursal disease virus. J Gen Virol (1988) 1.56
Inorganic pyrophosphate in plasma in normal persons and in patients with hypophosphatasia, osteogenesis imperfecta, and other disorders of bone. J Clin Invest (1971) 1.55
Diphosphonates. Experimental and clinical aspects. J Bone Joint Surg Br (1973) 1.54
Individual somatic H1 subtypes are dispensable for mouse development even in mice lacking the H1(0) replacement subtype. Mol Cell Biol (2001) 1.52
1,25-dihydroxycholecalciferol and 1alpha-hydroxycholecalciferol in hypoparathyroidism. Lancet (1974) 1.49
Is 24,25-dihydroxycholecalciferol a calcium-regulating hormone in man? Br Med J (1978) 1.49
Diphosphonates in Paget's disease. Lancet (1974) 1.47
Spinal cord dysfunction in Paget's disease of bone. Has medical treatment a vascular basis? J Bone Joint Surg Br (1981) 1.46
Human synovium releases a factor which stimulates chondrocyte production of PGE and plasminogen activator. Nature (1980) 1.45
Recovery from lethal herpes simplex virus type 1 infection is mediated by cytotoxic T lymphocytes. Infect Immun (1983) 1.43
Production of osteocalcin by human bone cells in vitro. Effects of 1,25(OH)2D3, 24,25(OH)2D3, parathyroid hormone, and glucocorticoids. Metab Bone Dis Relat Res (1984) 1.42
Intravenous clodronate in the treatment and retreatment of Paget's disease of bone. Lancet (1985) 1.42
Overview of bisphosphonates. Cancer (1997) 1.40
Paget's disease of bone. Experience with a diphosphonate (disodium etidronate) in treatment. Q J Med (1973) 1.40
The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res (1998) 1.39
Inhibitors and promoters of stone formation. Kidney Int (1978) 1.38
Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res (1998) 1.36
The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats. Calcif Tissue Res (1970) 1.35
Expression of tissue transglutaminase in skeletal tissues correlates with events of terminal differentiation of chondrocytes. J Cell Biol (1993) 1.35
Effect of bisphosphonates on proliferation and viability of mouse bone marrow-derived macrophages. J Bone Miner Res (1987) 1.35
Molecular mechanisms of action of bisphosphonates. Bone (1999) 1.33
Comparison of Escherichia coli strains recovered from human cystitis and pyelonephritis infections in transurethrally challenged mice. Infect Immun (1998) 1.32
Treatment of renal bone disease with 1 alpha-hydroxylated derivatives of vitamin D3. Clinical, biochemical, radiographic and histological responses. Q J Med (1979) 1.32
Structure-activity relationships of various bisphosphonates. Calcif Tissue Int (1983) 1.31
Stimulation of the proliferation of human bone cells in vitro by human monocyte products with interleukin-1 activity. J Clin Invest (1985) 1.30
Enterotoxin and cytotoxin production by enteroinvasive Escherichia coli. Infect Immun (1990) 1.30
The interrelationship between thromboxane biosynthesis, aggregation and 5-hydroxytryptamine secretion in human platelets in vitro. Thromb Haemost (1980) 1.30
Myositis ossificans progressiva. Clinical features of eight patients and their response to treatment. J Bone Joint Surg Br (1976) 1.30
Inorganic phosphate homeostasis. Renal adaptation to the dietary intake in intact and thyroparathyroidectomized rats. J Clin Invest (1976) 1.29
Localization of the murine reduced folate carrier as assessed by immunohistochemical analysis. Biochim Biophys Acta (2001) 1.29
Hypophosphatasia and the extracellular metabolism of inorganic pyrophosphate: clinical and laboratory aspects. Crit Rev Clin Lab Sci (1991) 1.28
The effects of diphosphonates on the growth and glycolysis of connective-tissue cells in culture. Biochem J (1978) 1.26
Estrogen inhibits release of tumor necrosis factor from peripheral blood mononuclear cells in postmenopausal women. J Bone Miner Res (1990) 1.25
Diphosphonates and Page's disease of bone. Lancet (1971) 1.24
Cell-mediated immunity to herpes simplex virus: recognition of type-specific and type-common surface antigens by cytotoxic T cell populations. Infect Immun (1981) 1.24
Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology (1996) 1.24
BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res (1991) 1.23
Epidemiology and etiology of diarrhea in colony-born Macaca nemestrina. Lab Anim Sci (1987) 1.20
Development of an in vitro model for study of non-O1 Vibrio cholerae virulence using Caco-2 cells. Infect Immun (1990) 1.20
Rescue of embryonic lethality in reduced folate carrier-deficient mice by maternal folic acid supplementation reveals early neonatal failure of hematopoietic organs. J Biol Chem (2001) 1.18
The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. Eur J Clin Invest (1970) 1.18
Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption. Osteoporos Int (1993) 1.18
Can bisphosphonates be given to patients with fractures? J Bone Miner Res (2001) 1.18
Metabolism of inorganic pyrophosphate (PPi). Arthritis Rheum (1976) 1.17
In vitro activation of human chondrocytes and synoviocytes by a human interleukin-1-like factor. Arthritis Rheum (1984) 1.17
Pathogenesis of chondrocalcinosis and pseudogout. Metabolism of inorganic pyrophosphate and production of calcium pyrophosphate dihydrate crystals. Ann Rheum Dis (1983) 1.17
Cloning, characterization, and chromosomal mapping of a phospholipase (lecithinase) produced by Vibrio cholerae. Infect Immun (1997) 1.15
Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism. J Bone Miner Res (1996) 1.15
Changes in the renal and extrarenal handling of phosphate induced by disodium etidronate (EHDP) in man. Clin Sci Mol Med (1975) 1.15
Diphosphonates in the treatment of myositis ossificans. Lancet (1969) 1.14
1,25-Dihydroxyvitamin D3 and human bone-derived cells in vitro: effects on alkaline phosphatase, type I collagen and proliferation. Endocrinology (1986) 1.14
Human myeloma cells shed the interleukin-6 receptor: inhibition by tissue inhibitor of metalloproteinase-3 and a hydroxamate-based metalloproteinase inhibitor. Br J Haematol (1998) 1.11
Influence of dichloromethylene diphosphonate (Cl2MDP) and calcitonin on bone resorption, lactate production and phosphatase and pyrophosphatase content of mouse calvaria treated with parathyroid hormone in vitro. Calcif Tissue Res (1973) 1.11